SCHEMBL24288784

SCHEMBL24288784

Nc1cccc(N2CCC(c3ccccc3)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.53
DHFR P00374 3/20 0.48
FAAH O00519 1/20 0.47
IP6K1 Q92551 1/20 0.47
HTR6 P50406 1/20 0.46
C1S P09871 1/20 0.46
HDAC4 P56524 2/20 0.45
SLC18A3 Q16572 2/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
GFER P55789 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
GRIN2B Q13224 1/20 0.42
DRD2 P14416 1/20 0.42
NPY1R P25929 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16081547 0.92 DHFR (0.48) ADRA2CDHFRFAAHIP6K1HTR6
SCHEMBL7446491 0.84 MBTD1 (0.55) DHFRSLC18A3LMNAGRIN2BDRD2
SCHEMBL241159 0.83 DHFR (0.50) ADRA2CDHFRIP6K1C1SSLC18A3
SCHEMBL16763481 0.83 SLC18A3 (0.47) ADRA2CDHFRSLC18A3ALDH1A1LMNA
SCHEMBL2627250 0.80 ADRA2C (0.71) ADRA2CALDH1A1LMNAMAPTMAPK1
SCHEMBL16943040 0.79 ADRA2C (0.59) ADRA2CALDH1A1LMNAMAPTMAPK1
SCHEMBL12005544 0.78 C1S (0.47) DHFRFAAHIP6K1C1SSLC18A3
SCHEMBL27339698 0.78 CARM1 (0.46) FAAHIP6K1HTR6HDAC4SLC18A3
SCHEMBL24289002 0.78 IP6K1 (0.49) FAAHIP6K1HTR6C1SHDAC4
SCHEMBL6942579 0.78 ADRA2C (0.80) ADRA2CHTR6ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050428-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-15 US disclosed
EP-4225749-A1 COMPOUNDS AND METHODS OF TREATING CANCERS Cullgen (Shanghai), Inc. (CN) 2023-08-16 EP disclosed
CN-116583509-A Compounds and methods for treating cancer 上海睿跃生物科技有限公司 2023-08-11 CN disclosed
WO-2022073469-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2022-04-14 WO disclosed
WO-2022073469-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240050428-A1 COMPOUNDS AND METHODS OF TREATING CANCERS GSPT1, GGT1, VHL ADRA2C 4474/4885DHFR 316/4885FAAH 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.